Ocuphire Pharma (OCUP) Gets a Buy Rating from JonesTrading

In a report released today, Prakhar Agrawal from JonesTrading initiated coverage with a Buy rating on Ocuphire Pharma (OCUP) and a price target of $20.00. The company’s shares closed last Thursday at $5.79.

According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -3.6% and a 41.7% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Phathom Pharmaceuticals, and Aldeyra Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocuphire Pharma with a $21.67 average price target, representing a 269.8% upside. In a report issued on April 5, Alliance Global Partners also initiated coverage with a Buy rating on the stock with a $25.00 price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts